As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

In relief to Bristol-Myers Squibb Holdings Ireland (BMS), the Delhi High Court has upheld its patent for the anti-cancer drug ...

Bristol Myers Squibb today announced the appointment of Karen Costello as the new General Manager for its commercial operations in Ireland. In this new role, Karen will lead the delivery of Bristol ...

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, ...

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $113.5 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Bristol-Myers Squibb will enter into a collaborative agreement with AstraZeneca, in order to develop and commercialise Amylin’s existing portfolio of products, which has a main focus on the R ...

Bristol-Myers Squibb Company in the Anxiety Disorder Treatment market. In 2023, the Anxiety Disorder Treatment market (不安障害治療薬 市場 ) was valued at US$ 11.8 Billion. The market is forecast to grow at a ...